Anti-tuberculosis Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Anti-tuberculosis Therapeutics Market Analysis
The Anti-tuberculosis (TB) Therapeutics Market is expected to witness a CAGR of 6.2% during the forecast period (2022 - 2027).
The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic and treatment procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the data, it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has significantly impacted the market growth during the pandemic.
Certain factors that are propelling the market growth are the rising prevalence of tuberculosis, a growing initiative from government organizations for tuberculosis awareness, and the rising incidence of multi-drug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) cases in developing countries.
The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic and treatment procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the d, it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has negatively impacted the market growth during the pandemic.
Additionally, the rising incidence of multi-drug resistant tuberculosis (MDR-TB) and XDR in developing countries is also expected to boost market growth over the forecast period. For instance, according to an article published by the Journal of Family Medicine and Primary Care, in January 2022, titled 'Status of drug-resistant tuberculosis among patients attending a tuberculosis unit of West Bengal', it has been observed that the prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) is highest in India and ranks first in the global ranking of detecting new cases each year. In addition, as per the same source, an estimated overall incidence of tuberculosis in India was 193 per lakh people, in 2020.
Furthermore, the growing government initiatives in creating awareness among the population regarding tuberculosis (TB) are also expected to propel market growth over the forecast period. For instance, in March 2021, Dr. Harsh Vardhan, Union Minister for Health and Family Welfare launched the 'Tribal TB Initiative' along with Shri Arjun Munda, Union Minister for Tribal Affairs in the presence of Shri Ashwini Kumar Choubey, Minister of State for Health and Family Welfare in India. Also, in July 2019, the State Council of China released the Healthy China Initiative 2019-2030, which included 15 special campaigns, including the Tuberculosis Control Action to guide the way for China's TB prevention and control. Hnece, these factors are expected to boost the market growth.
However, the adverse side effects of anti-tuberculosis drugs and the high cost of MDR and XDR TB drugs are likely to impede the market growth over the forecast period.
Anti-tuberculosis Therapeutics Market Trends
This section covers the major market trends shaping the Anti-tuberculosis Therapeutics Market according to our research experts:
Isoniazid Segment Expects to Register a High CAGR in the Anti-tuberculosis Therapeutics Market Over the Forecast Period
Isoniazid, also known as an isonicotinic acid hydrazide, is an antibiotic used for the treatment of tuberculosis. It inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor.
The isoniazid segment is expected to witness significant growth in the anti-tuberculosis therapeutics market over the forecast period owing to the factors such as the rising prevalence of tuberculosis and the adoption of isoniazid as a treatment for tuberculosis and the rising company activities in conducting clinical trials. For instance, according to an article published by the American Journal of Respiratory and Critical Care Medicine, in June 2020, titled 'High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis', it has been observed that the high dose isoniazid has an early bactericidal activity for Mycobacterium tuberculosis (MTB) strains with inhA mutations. In addition, as per the same source, for individuals with isolated inhA mutations and rifampicin-resistant tuberculosis (TB), high-dose isoniazid is a helpful addition to second-line TB therapy regimens. This is expected to increase the growth of the segment, thereby propelling the market growth over the forecast period.
Also, in February 2021, five African countries, namely Ethiopia, Ghana, Kenya, Mozambique, and Zimbabwe, have piloted a new short-short course tuberculosis treatment regime, a fixed dose-combination of rifapentine and isoniazid, that helps in reducing the pills burden from nine to three pills a week for adults. Thus, the increasing adoption of isoniazid in combination with other drugs for treating tuberculosis is expected to fuel the segment growth over the forecast period.
Therefore, the due to aforementioned factors the studied market is expected to increase over the forecast period.
North America Dominates the Market and Expects to do Same Over the Forecast Period
North America is expected to dominate the tuberculosis therapeutics market owing to the factors such as the rising number of tuberculosis cases in the region, the presence of well-established healthcare infrastructure, and high healthcare spending.
The rising incidence of tuberculosis in the region is the key factor driving the market growth. For instance, according to the Centers for Disease Control and Prevention's National Tuberculosis Surveillance System (NTSS), a total of 7,860 tuberculosis cases were reported in the 50 United States and the District of Columbia (DC), in 2021. The national incidence of reported tuberculosis cases (cases per 100,000 people) increased by 9.4% in 2021 (2.37) as compared to 2020. In addition, as per the same source, the increase in tuberculosis cases among the population in 2021 was due to the delayed diagnosis of cases in persons with symptom onset during 2020. Also, as per the same source, in 2021, some of the countries with the highest number of tuberculosis cases were California (1,750), Texas (991), Florida (499), Pennsylvania (166), Ohio (149), and Arizona (129). Thus, the growing burden of tuberculosis among the population is expected to raise the demand for effective drugs which is expected to increase the market growth over the forecast period.
In addition, the rising healthcare spending in the region is expected to increase the company's activities for developing effective and safe drugs, thereby propelling the market growth. For instance, according to the Organization for Economic Co-operation and Development (OECD), 2022, United States healthcare spending, as percent share of GDP, in 2021 was around 17.8%. Additionally, as per the data published by the Centers for Medicare & Medicaid Services (CMS), in March 2022, titled 'CMS Office of the Actuary Releases 2021-2030 Projections of National Health Expenditures', it has been observed that the annual growth in national health spending is expected to average 5.1% over 2021-2030. In addition, the National Health Spending in 2020 was USD 4.1 trillion and it is projected to reach USD 6.8 trillion by 2030.
Therefore, the due to aforementioned factors the studied market is expected to increase over the forecast period.
Anti-tuberculosis Therapeutics Industry Overview
The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in research and development, more small to mid-sized companies are estimated to enter the market in the coming future. Some of the companies in the market are Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson holds the largest market share.
Anti-tuberculosis Therapeutics Market Leaders
-
Macleods Pharmaceuticals Ltd
-
Otsuka Pharmaceutical Co. Ltd
-
Johnson and Johnson
-
Sequella, Inc.
-
Lupin Limited
*Disclaimer: Major Players sorted in no particular order
Anti-tuberculosis Therapeutics Market News
- In March 2022, Johnson & Johnson India launched a youth-focused, digital initiative, Be The Change For TB, a joint initiative with the Union Ministry of Health's Central TB Division and the United States Agency for International Development, as part of its corporate pledge against tuberculosis.
- In September 2021, TB Alliance, a non-profit drug developer, granted a non-exclusive license to Lupin for developing the anti-TB drug pretomanid as part of the three-drug 'BPaL' regimen. Under the license, Lupin commercializes the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Anti-tuberculosis Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Tuberculosis
- 4.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness
- 4.2.3 Rising Incidence of MDR and XDR Cases in Developing Countries
-
4.3 Market Restraints
- 4.3.1 Adverse Side Effects of Anti-tuberculosis Drugs
- 4.3.2 High Cost of MDR and XDR TB Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Isoniazid
- 5.1.2 Rifampin
- 5.1.3 Ethambutol
- 5.1.4 Pyrazinamide
- 5.1.5 Fluoroquinolones
- 5.1.6 Bedaquiline
- 5.1.7 Amynoglycosides
- 5.1.8 Thioamides
- 5.1.9 Cyclic Peptides
- 5.1.10 Other Drug Classes
-
5.2 By End User
- 5.2.1 Hospitals and Clinics
- 5.2.2 Government Agencies
- 5.2.3 Non Profit Organizations
- 5.2.4 Other End Users
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Lupin Limited
- 6.1.2 Macleods Pharmaceuticals Ltd
- 6.1.3 Otsuka Pharmaceutical Co. Ltd
- 6.1.4 Johnson and Johnson
- 6.1.5 Sequella, Inc.
- 6.1.6 Novartis AG
- 6.1.7 Akorn Operating Company LLC
- 6.1.8 Fresenius SE & Co. KGaA
- 6.1.9 Viatris Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAnti-tuberculosis Therapeutics Industry Segmentation
As per the scope of the report, Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it remains one of the most common causes of death among adults, particularly in emerging economies. The Anti-tuberculosis Therapeutics Market is segmented by Drug Class (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Aminoglycosides, Thioamides, Cyclic Peptides, and Other Drug Classes), End User (Hospitals and Clinics, Government Agencies, Non-Profit Organizations, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug Class | Isoniazid | |
| Rifampin | ||
| Ethambutol | ||
| Pyrazinamide | ||
| Fluoroquinolones | ||
| Bedaquiline | ||
| Amynoglycosides | ||
| Thioamides | ||
| Cyclic Peptides | ||
| Other Drug Classes | ||
| By End User | Hospitals and Clinics | |
| Government Agencies | ||
| Non Profit Organizations | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Anti-tuberculosis Therapeutics Market Research FAQs
What is the current Global Anti-tuberculosis Therapeutics Market size?
The Global Anti-tuberculosis Therapeutics Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Global Anti-tuberculosis Therapeutics Market?
Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Sequella, Inc. and Lupin Limited are the major companies operating in the Global Anti-tuberculosis Therapeutics Market.
Which is the fastest growing region in Global Anti-tuberculosis Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Anti-tuberculosis Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Anti-tuberculosis Therapeutics Market.
What years does this Global Anti-tuberculosis Therapeutics Market cover?
The report covers the Global Anti-tuberculosis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Anti-tuberculosis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
South Korea Patient Monitoring Industry Report
Statistics for the 2024 South Korea Patient Monitoring market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. South Korea Patient Monitoring analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
